VANCOUVER, March 12, 2018 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel…
